Scleroderma is a rare autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. It is estimated that the prevalence of scleroderma varies worldwide, with approximately 240 cases per million people. However, it is important to note that these numbers may vary depending on the population studied and the diagnostic criteria used.
Systemic sclerosis, the most severe form of scleroderma, affects approximately 75,000 to 100,000 individuals in the United States. It is more common in women than men, with a female-to-male ratio of about 3:1. The disease typically manifests between the ages of 30 and 50, although it can occur at any age.
Localized scleroderma, a milder form of the disease, is estimated to affect about 2 to 20 per 100,000 individuals. It often begins in childhood or adolescence and is more common in females.
While scleroderma is considered a rare disease, it can have a significant impact on the quality of life for those affected. Early diagnosis and appropriate treatment are crucial in managing the symptoms and preventing complications.